Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Patrick Ott, MD, PhD
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01970358CT.gov A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma | — | Completed | — | — | — |
NCT01103635CT.gov Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT01008527CT.gov Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Selicrelumab (this asset) | Patrick Ott, MD, PhD | P1 | CCC · 48 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Ipilimumab | M.D. Anderson Cancer Center | P4 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
| Sargramostim | Mayo Clinic | P3 | BB |
| Pembrolizumab | Biocon Biologics UK PLC | P4 | BB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
+42 more in the Melanoma cohort
Other indications for Selicrelumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Adenocarcinoma | — | P1/2 | B · 60 |
| Neoplasm | — | P1 | CCC · 53 |
| Metastatic Melanoma | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Selicrelumab in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/selicrelumab-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →